The biotech company reported second-quarter earnings and sold some drug development rights.
News & Analysis: Verastem
If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.
Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.
Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.
Healthcare bargain hunters can find good values in quality low-priced stocks.
VSTM earnings call for the period ending June 30, 2019.
VSTM earnings call for the period ending March 31, 2019.
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
Verastem's new oncology drug isn't setting the world on fire.
VSTM earnings call for the period ending December 31, 2018.